Citi analyst Liav Abraham weighed in on Endo International plc (NASDAQ: ENDP) following news Athenex lanched a compounded Vasopressin. Abraham said the headline is likely worse than reality.

The firm reiterated a Buy rating and price target of $19.00

For an analyst ratings summary and ratings history on Endo International plc click here. For more ratings news on Endo International plc click here.

Shares of Endo International plc closed at $15.65 yesterday.

Analyst Comments FDA Trader Talk

Endo International (ENDP) Reports Lift of Temporary Stay of FDA Litigation Following Launch of Bulk-Compounded Vasopressin Product by Section 503B Outsourcing FacilityAugust 15, 2018 6:05 AM Endo International plc (ENDP) PT Raised to $17 at Mizuho SecuritiesAugust 14, 2018 5:46 AM Endo International (ENDP) Weakness on Compounded Vasopressin Launch Bears Watching FDA Action - RBCAugust 13, 2018 11:39 AM Endo International plc (ENDP) PT Raised to $16 at BMO CapitalAugust 13, 2018 8:26 AM RBC Capital Upgrades Endo International plc (ENDP) to Outperform on Cycle Up-TurnAugust 13, 2018 4:51 AM PGA Golfer Tim Herron Teams Up with Endo Pharmaceuticals to Encourage Parents to Get Their Own Check-Ups This Back-to-School SeasonAugust 9, 2018 7:30 AM Endo International plc (ENDP) PT Raised to $19 at CitiAugust 9, 2018 6:58 AM Endo International plc (ENDP) PT Raised to $17 at Deutsche BankAugust 9, 2018 6:09 AM